PSY THERAPEUTICS, INC.
Brain-penetrant small molecule inhibitors of catechol-O-methyl transferase (COMT) for treating major depressive disorder
- Sector
- Biotech
- Headquarters
- Waltham, MA
- Latest Form D
- $2.8M, Dec 2021
- Total capital
- $7.2M
- Federal grants
- $458K
- 1 award · 2023
- Rank in peer group#295 of 502
- Private capital raised
- $6.7M
- 2 Form D · last Dec 2021
- 58 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 25 pending · first 2025
- Rank in peer group#57 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Development of brain-penetrant COMT inhibitors for the treatment of depressive disorders$458K
- Private capital raisedForm D · SEC · 2nd filing$2.8M
- Private capital raisedForm D · SEC · 1st filing$4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#57 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Alan S. CrossResearcherDirectorLinked by $458K in grants as PI
- Brant S. BinderExecutive Officer, DirectorNamed in SEC Form D filings
- Bryan S. RobertsDirectorNamed in SEC Form D filings
- Daniel S. Weiss PickDirectorNamed in SEC Form D filings
- David S. BarlowExecutive Officer, DirectorNamed in SEC Form D filings
- David S. BarlowExecutive Officer, DirectorNamed in SEC Form D filings
Show all 11 people
- Jeff S. TrodermanExecutive OfficerNamed in SEC Form D filings
- Jerry F. RosenbaumDirectorNamed in SEC Form D filings
- Jerry F. RosenbaumDirectorNamed in SEC Form D filings
- Paul F. MurphyDirectorNamed in SEC Form D filings
- William F. WagnerExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 26- PendingInhibiting Monoacylglycerol Lipase (magl)USPTOApplication 19078912
- PendingMonoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment And Management Of Pain And Related ConditionsUSPTOApplication 18724771
- PendingMonoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment Of Anxiety And Related ConditionsUSPTOApplication 18724766
Show all 26 patent records
- Inhibiting Monoacylglycerol Lipase (magl)Jul 3, 2025 · Application 19078912Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment And Management Of Pain And Related ConditionsMay 29, 2025 · Application 18724771Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment Of Anxiety And Related ConditionsMay 29, 2025 · Application 18724766Pending
- Inhibiting Monoacylglycerol Lipase (magl)Apr 29, 2025 · US 12,286,421Granted
- Inhibiting Monoacylglycerol Lipase (magl)Mar 13, 2025 · Application 18724744Pending
- Inhibiting Catechol-o-methyltransferase (comt)Application 63650745Pending
- Inhibiting Monoacylglycerol Lipase (magl)Application PCTUS2024024039Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment Of Neurological DisordersApplication 63539409Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment And Management Of Inflammatory ConditionsApplication 63539420Pending
- Inhibiting Monoacylglycerol Lipase (magl)Application 63526413Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment Of Neurological DisordersApplication 63525353Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment And Management Of Inflammatory ConditionsApplication 63525356Pending
- Inhibiting Monoacylglycerol Lipase (magl)Application 63459168Pending
- Inhibiting Monoacylglycerol Lipase (magl)Application PCTUS2022082554Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment And Management Of Pain And Related ConditionsApplication PCTUS2022082596Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment Of Anxiety And Related ConditionsApplication PCTUS2022082585Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment Of Anxiety And Related ConditionsApplication 63294752Pending
- Monoacylglycerol Lipase Inhibitors And Use ThereofApplication 63294747Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment And Management Of Pain And Related ConditionsApplication 63294756Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment And Management Of Inflammatory ConditionsApplication 19495103Pending
- Inhibiting Monoacylglycerol Lipase (magl)Application 19473925Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment Of Neurological DisordersApplication 19495098Pending
- Inhibiting Catechol-o-methyltransferase (comt)Application PCTUS2025030623Pending
- Inhibiting Catechol-o-methyltransferase (comt)Application 63714938Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment And Management Of Inflammatory ConditionsApplication PCTUS2024036856Pending
- Monoacylglycerol Lipase Inhibitors And Use Thereof For The Treatment Of Neurological DisordersApplication PCTUS2024036852Pending
Related companies, and why
- Tracon Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Holobiome, Inc.Similar federal contract value in Biotech · null in contracts
- KHLORIS BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- MindImmune Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Phenovista Biosciences LLCSimilar federal contract value in Biotech · null in contracts
- ELEGEN CORP.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .